SoftBank Vision Fund 2, a private equity firm, led a $150m Series C funding round in Dewpoint Therapeutics, a biotechnological company, with participation from General Catalyst, Mubadala Capital, 3E Bioventures Capital, Mirae Asset Capital, NS Investment, Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures. "We are delighted to have achieved this significant milestone, which allows us to welcome several high-calibre tech and biotech investors to our existing syndicate of innovative life-science investors. This latest financing will further accelerate our goal of developing breakthrough medicines to address a vast array of diseases resulting from dysregulation of biomolecular condensates," Ameet Nathwani, Dewpoint CEO.